Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma × mirvetuximab soravtansine × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 5 Fallopian Tube Neoplasms 5 Endometrial Neoplasms 3 Neoplasms 2 Triple Negative Breast Neoplasms 1 Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma 1 Carcinoma, Ovarian Epithelial 1

Interventions

mirvetuximab soravtansine 1 liposomal doxorubicin 1 Paclitaxel 1 Gemcitabine 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04274426 2025-04-06

MIROVA

AGO Research GmbH

Phase 2 Active not recruiting

Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡